论文部分内容阅读
本实验旨在研究顺铂和卡铂联合应用于非小细胞肺癌的安全性,以及加用本方法的有效性及必要性。对象:对适合手术的病例进行组织细胞学诊断,并按下列标准选择病例:1.未经治疗;2.有可能对病变进行监测;3.骨髓、肝、肾机能良好;4.生活分级0～2级;5.预计生存期在2个月以上;6.未满80岁的病例;7.有严重并发症者;8.经患者家属同意。方法:1.给药方法:一月内连续给予卡铂和顺铂,其剂量分别是CBDCA(卡铂)300mg/m~2,CDPP(顺铂)80mg/m~2,同时应用利尿剂、止吐剂及5HT阻断剂。至少2个
This experiment was designed to investigate the safety of cisplatin and carboplatin for non-small cell lung cancer and the effectiveness and necessity of this method. Subject: Hepatic histological diagnosis was performed on the suitable cases and the cases were selected according to the following criteria: 1. No treatment; 2. Possible monitoring of the lesions; 3. Good bone marrow, liver, and kidney function; 4. Life classification 0 Grade 2; 5. Life expectancy of more than 2 months; 6. Cases under 80 years of age; 7. Serious complications; 8. With the consent of the patient’s family. Methods: 1. Administration method: Carboplatin and cisplatin were continuously administered within one month. The doses were 300mg/m 2 for CBDCA (carboplatin), 80mg/m 2 for CDPP (cisplatin), and diuretics. Antiemetic and 5HT blockers. At least 2